Skip to main content
Fig. 2 | BMC Neurology

Fig. 2

From: Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis

Fig. 2

Meta-analysis of mean adherence rate as determined by a) MPR or b) PDC. Note: For studies for which results for treatment-naive and treatment-experienced patients were reported separately (combined data were not available), data were combined; for studies reporting data for more than 1 oral DMD (combined data were not reported), data were combined; for studies reporting data for subgroups (combined data were not reported), data were combined. The area of each grey square is proportional to the study’s weight in the meta-analysis. Weight values are rounded. Abbreviations: CI, confidence interval; DMD, disease-modifying drug; MPR, medication possession ratio; MRAW, raw mean; PDC, proportion of days covered

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us